Key features and details
- Expression system: HEK 293 cells
- Purity: > 95% SDS-PAGE
- Endotoxin level: < 1.000 Eu/µg
- Active: Yes
- Tags: Fc tag N-Terminus
- Suitable for: SDS-PAGE, Functional Studies
Product nameRecombinant mouse TRAP/CD40L protein (Fc Chimera Active)
See all TRAP/CD40L proteins and peptides
Measured by its binding ability in a functional ELISA. Immobilized Mouse CD40, His Tag (ab220566) at 5 μg/mL (100 μL/well) can bind Recombinant mouse TRAP/CD40L protein (Fc Chimera Active) (ab220586) with a linear range of 1-16 ng/mL.
Purity> 95 % SDS-PAGE.
Endotoxin level< 1.000 Eu/µg
Expression systemHEK 293 cells
Protein lengthProtein fragment
SequenceGDEDPQIAAHVVSEANSNAASVLQWAKKGYYTMKSNLVMLENGKQLTVKR EGLYYVYTQVTFCSNREPSSQRPFIVGLWLKPSSGSERILLKAANTHSSS QLCEQQSVHLGGVFELQAGASVFVNVTEASQVIHRVGFSSFGLLKL
Predicted molecular weight43 kDa including tags
Amino acids115 to 260
TagsFc tag N-Terminus
Additional sequence informationFused with a human IgG1 Fc tag at the N-terminus.
Our Abpromise guarantee covers the use of ab220586 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
After reconstitution this product is stable for 3 months at -80°C under sterile conditions.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. Please see notes section.
Constituents: 0.61% Tris, 0.75% Glycine, 5% Trehalose, 0.44% L-Arginine, 0.87% Sodium chloride
Lyophilized from 0.22 µm filtered solution.
5-10% trehalose is commonly used for freeze drying, and after reconstitution, the trehalose is mostly about 3-5%
This product is an active protein and may elicit a biological response in vivo, handle with caution.
ReconstitutionReconstitute with sterile deionized water to a concentration of 200 µg/ml.
- CD 40L
- CD40 antigen ligand
FunctionMediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL-4. Involved in immunoglobulin class switching.
Release of soluble CD40L from platelets is partially regulated by GP IIb/IIIa, actin polymerization, and an matrix metalloproteinases (MMP) inhibitor-sensitive pathway.
Tissue specificitySpecifically expressed on activated CD4+ T-lymphocytes.
Involvement in diseaseDefects in CD40LG are the cause of X-linked immunodeficiency with hyper-IgM type 1 (HIGM1) [MIM:308230]; also known as X-linked hyper IgM syndrome (XHIM). HIGM1 is an immunoglobulin isotype switch defect characterized by elevated concentrations of serum IgM and decreased amounts of all other isotypes. Affected males present at an early age (usually within the first year of life) recurrent bacterial and opportunistic infections, including Pneumocystis carinii pneumonia and intractable diarrhea due to cryptosporidium infection. Despite substitution treatment with intravenous immunoglobulin, the overall prognosis is rather poor, with a death rate of about 10% before adolescence.
Sequence similaritiesBelongs to the tumor necrosis factor family.
modificationsThe soluble form derives from the membrane form by proteolytic processing.
N-linked glycan is a mixture of high mannose and complex type. Glycan structure does not influence binding affinity to CD40.
Cellular localizationSecreted and Cell membrane.
- Information by UniProt
Immobilized Mouse CD40, His Tag (ab220566) at 5 μg/mL (100 μL/well) can bind Recombinant mouse TRAP/CD40L protein (Fc Chimera Active) (ab220586) with a linear range of 1-16 ng/mL.
SDS-PAGE analysis of ab220586 stained overnight with Coomassie Blue.
Lane 1: Reducing conditions.
Lane 2: Non-reducing conditions.
As a result of glycosylation, the protein migrates as 52 kDa under reducing conditions and 90-116 kDa under non-reducing conditions on SDS-PAGE gel.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab220586 has not yet been referenced specifically in any publications.